A Phase II study of chemotherapy and immune checkpoint blockade with Pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma
Study for Patients with Gastric Cancer Using Study Drug Pembrolizumab
Sponsor: Merck Sharp & Dohme Corp.
Enrolling: Male and Female Patients
IRB Number: AAAQ9871
U.S. Govt. ID: NCT02918162
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the effectiveness of combining immune therapy with standard chemotherapy. People who usually have this are treated with 3 cycles of standard chemotherapy, followed by surgery, and then another 3 cycles of chemotherapy. In this study, all study subjects will receive the standard of care chemotherapy for 3 cycles prior to and 3 cycles following surgery, combined with immune therapy with an additional cycle of immune therapy (4 total) in the pre-operative period. The chemotherapy administered in this study is not the identical regimen that showed benefit in earlier clinical trials. Rather it will be the standard combination that your doctor determines is the most appropriate regimen for you whether or not you participate in this clinical trial.
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Have you been diagnosed with gastric cancer? Yes No
Are you able to walk and care for yourself and do light physical activity like light housework or office work? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162